ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025 (Form 8-K)

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025

For Immediate Release

PORTLAND, Maine - July 9, 2025 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2025.

Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close of the quarter. The Company expects to continue providing this prompt, preliminary report on product sales until further notice going forward.

As displayed in the table above, product sales increased by 18%, 14%, 25% and 22% during the three-month, six-month, nine-month and twelve-month periods ended June 30, 2025 in comparison to the same periods ended June 30, 2024, respectively.

With increased production output, the Company has now met current customer demand and reduced the order backlog to under $100,000 as of June 30, 2025, which largely reflects normal timing differences between order dates and shipment dates and is down from approximately $3.4 million as of May 6, 2025. The recent sales pace reflects, in part, the replenishment of the distribution pipeline following an extended period during which product supply fell short of demand. During that time, distributors operated with minimal to no buffer inventory stock. Now that distribution inventories have been rebuilt, the Company is back to shipping within one week of order receipt. As a result, the Company's commercial team has transitioned its focus from managing product allocations to pursuing new business and re-engaging customers affected during the period of short supply.

"Our investments to increase production capacity to over $30 million per year were challenging and did take longer than we had planned. We are now evaluating incremental liquid processing and freeze-drying investments to increase capacity by an additional 33% to approximately $40 million or more to capitalize on potential demand growth in the North American dairy and beef markets," commented Michael F. Brigham, President and CEO of ImmuCell. "Although buffer stock replenishment and backlog depletion may result in one-time lifts in volume, our teams remain focused on the sustainable, long-term growth of the First Defense^® product line."

As previously disclosed by the Company, the Company is initiating Investigational Product use of Re-Tain^® to test market acceptance of the product over the last six months of 2025. This exciting initiative reflects the innovative nature of this novel product and its safety profile and allows us to utilize available inventory before shelf-life expiration to collect critical product performance data. This opportunity is not, however, expected to generate significant revenue or profit. The Company made its Non-Administrative New Animal Drug Application (NADA) submission, that included its fourth submission of the CMC Technical Section, together with the minor technical sections covering All Other Information and Product Labeling during early January of 2025. Clearing inspectional observations at the facilities of the Company's contract manufacturer is still the critical path constraint to NADA approval.

Conference Call:

The Company is planning to host a conference call on Friday, August 15, 2025, at 9:00 AM ET to discuss the unaudited financial results for the quarter ended June 30, 2025. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until August 22, 2025, at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #5659118. Investors are encouraged to review the Company's Corporate Presentation slide deck that provides an overview of the Company's business and is available under the "Investors" tab of the Company's website at www.immucell.com, or by request to the Company. An updated version of the slide deck is expected to be made available after the market closes on Thursday, August 14, 2025.

About ImmuCell:

ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense^®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain^®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal label restrictions that provides an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.